Abstract
Thromboxane A2 (TXA2) is a labile product formed from arachidonic acid by cyclooxygenase. The pathogenesis of numerous cardiovascular, pulmonary, and thromboembolic diseases can be related to this metabolite. Therefore, TXA2 modulators have been developed for 20 years. This review will highlight the evolution in the field of TXA2 modulators.
Keywords: thromboxane a2, arachidonic acid, thromboxane synthase, prostanoids
Mini-Reviews in Medicinal Chemistry
Title: New Developments on Thromboxane Modulators
Volume: 4 Issue: 6
Author(s): Jean-Michel Dogne, Julien Hanson, Xavier de Leval, Bernard Masereel, Philippe Kolh and Bernard Pirotte
Affiliation:
Keywords: thromboxane a2, arachidonic acid, thromboxane synthase, prostanoids
Abstract: Thromboxane A2 (TXA2) is a labile product formed from arachidonic acid by cyclooxygenase. The pathogenesis of numerous cardiovascular, pulmonary, and thromboembolic diseases can be related to this metabolite. Therefore, TXA2 modulators have been developed for 20 years. This review will highlight the evolution in the field of TXA2 modulators.
Export Options
About this article
Cite this article as:
Dogne Jean-Michel, Hanson Julien, Leval de Xavier, Masereel Bernard, Kolh Philippe and Pirotte Bernard, New Developments on Thromboxane Modulators, Mini-Reviews in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1389557043403684
DOI https://dx.doi.org/10.2174/1389557043403684 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface [Hot topic: Diabetes (Guest Editor: Alex M. DePaoli)]
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Potential Pathogenic Inflammatory Mechanisms of Endothelial Dysfunction Induced by Type 2 Diabetes Mellitus
Current Pharmaceutical Design Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Salvianolic Acid B Inhibits Atherogenesis of Vascular Cells through Induction of Nrf2-dependent Heme Oxygenase-1
Current Medicinal Chemistry From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Congenital Abnormalities: Consequence of Maternal Zika Virus Infection: A Narrative Review
Infectious Disorders - Drug Targets Preconception Care for Diabetic Women: Background, Barriers, and Strategies for Effective Implementation
Current Diabetes Reviews Impact of 13Valent Vaccine for Prevention of Pneumococcal Diseases in Children and Adults at Risk: Possible Scenarios in Campania Region
Infectious Disorders - Drug Targets Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
Current Chemical Biology Ouabain Antagonists as Antihypertensive Agents
Current Pharmaceutical Design Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Cardioprotection with Sildenafil: Implications for Clinical Practice
Current Medicinal Chemistry